Drouin, M. A., Kollmannsberger, C. K., Uronis, H. E., Martell, R. E., Wang, J., Dubay, M., … Shapiro, G. (2010). Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265-101). In Journal of Clinical Oncology (Vol. 28, pp. 3106–3106). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2010.28.15_suppl.3106

Drouin, M. A., C. K. Kollmannsberger, H. E. Uronis, R. E. Martell, J. Wang, M. Dubay, I. Dupont, J. M. Besterman, H. Hurwitz, and G. Shapiro. “Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265-101).” In Journal of Clinical Oncology, 28:3106–3106. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.3106.

Drouin MA, Kollmannsberger CK, Uronis HE, Martell RE, Wang J, Dubay M, et al. Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265-101). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 3106–3106.

Drouin, M. A., et al. “Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265-101).” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2010, pp. 3106–3106. Crossref, doi:10.1200/jco.2010.28.15_suppl.3106.

Drouin MA, Kollmannsberger CK, Uronis HE, Martell RE, Wang J, Dubay M, Dupont I, Besterman JM, Hurwitz H, Shapiro G. Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265-101). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 3106–3106.